Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | Interferon in polycythemia vera: long – term experience from a single center

Richard Silver • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Interferon Ropeginterferon alfa-2a Ropeginterferon alfa-2b

Richard Silver, MD, Weill Cornell Medical College, New York, NY, gives a presentation on the long-term outcomes of interferon use in polycythemia vera (PV) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Richard Silver

The role of rusfertide in polycythemia vera
3:23
The role of rusfertide in polycythemia vera
Richard Silver • 18 Oct 2022
The role of interferon in polycythemia vera & perspectives on the management of low-risk patients
6:49
The role of interferon in polycythemia vera & perspectives on the management of low-risk patients
Richard Silver • 18 Oct 2022
Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF
6:19
Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF
Richard Silver • 18 Oct 2022
Looking forward to the 2022 MPN Congress
2:50
Looking forward to the 2022 MPN Congress
Richard Silver • 18 Oct 2022

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Richard Silver • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Richard Silver • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Richard Silver • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Richard Silver • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals